was 11%. Incidence of chronic GVHD was 20%, severe chronic GVHD was 4%. 5 children died due to transplant related mortality (TRM), all of them were class 3 Thalassemia; 2 patients transplanted from unrelated donor and unrelated cord and 2 died after second HSCT. Causes of deaths were severe infections secondary to engraftment failure; severe hemorrhagic cystitis and multiorgan failure; pulmonary and intracranial bleeding during engraftment and TTP. 1 child died 3.5 years after HSCT from severe multisystemic GVHD and complications of immunosuppressive therapy. Conclusion: Our results showed that children with hemoglobinopathy who received HSCT had excellent results with survival above 80% despite of majority of patients with class 3 Thalassemia and number of children who underwent second HSCT. Factors affecting prognosis were: advanced class of Thalassemia type of donor and second HSCT with myeloablative regimen. Engraftment failure continues to be a problem for Thalassemia patients. There is a need for controlled trials to evaluate the effectiveness of different treatment regimens for specific group of patients.
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